HomeAI · summaries
Storia in 5 fonti
Novartis supera le attese, BofA conferma buy: i 5 studi clinici di fase III da seguire nel secondo semestre 2026 | MilanoFinanza News
Migliori del previsto i ricavi a 14,4 miliardi di dollari e l’utile operativo a 5,94 miliardi nel secondo trimestre. La guidance 2026 poteva essere alzata secondo gli analisti
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Novartis climbs on upbeat drug sales as key readouts loom
A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
- ·
france24.com
Novartis says buoyed by new treatments in second quarter
Swiss pharmaceuticals giant Novartis said Tuesday that group sales exceeded expectations in the second quarter of 2026, on the back of a range of new products.
